A court has approved the $305m sale of 23andMe’s assets to a nonprofit led by former 23andMe CEO Anne Wojcicki.

Notably, the first FDA-approved biologic was dupilumab (Dupixent; Regeneron, Sanofi), and this approval took place less than 1 year ago in September 2024. Khavandi: Inhaled therapy — viewed as a ...

Nektar Therapeutics (NASDAQ: NKTR) stock exploded nearly 157% following news that Rezpeg, the company’s experimental ...

But the surge in Chinese pharma is still ringing alarm bells. “China’s rise in biotech is a threat to the United States,” ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected to advance at ...

The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected to advance at ...

With CT scans picking up more cases of sclerosing mesenteritis, be prepared to diagnose this poorly understood autoimmune ...

Indian drugmaker Biocon has announced that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...